1. At a Glance – A Pharma Company That Looks Like a Corporate Thriller
Market Cap: ₹121 Cr
Current Price: ₹34.3
52-Week High/Low: ₹76 / ₹30.6
3-Month Return: -25.2%
1-Year Return: -53.2%
ROCE: -17.4%
ROE: -16.3%
Debt: ₹20.1 Cr
TTM Sales: ₹25.5 Cr
TTM PAT: ₹-16.4 Cr
OPM: -67.1%
Let me translate this politely: Pharmaids Pharmaceuticals is a pharma company where losses are more consistent than profits. Sales are growing (24% TTM growth), but margins are behaving like they’re allergic to profitability. The company just reported ₹5.43 Cr in Q3 FY26 sales with a ₹-2.65 Cr net loss. Meanwhile, an open offer happened at ₹62.15 per share, and today the stock trades almost half of that. That’s not a gap — that’s a canyon.
And the best part? Promoter holding jumped from micro-single digits to 32.99% in Dec 2025 after open offer and reclassification drama.
So the question is simple:
Is this a turnaround story… or a case study for MBA students titled “How Not To Run a Pharma Company”?
Let’s investigate.
2. Introduction – From Vitamins to Volatility
Pharmaids Pharmaceuticals Ltd, incorporated in 1989, manufactures bulk drugs and intermediaries. Sounds simple. Respectable. Stable.
But this company’s recent history reads like a daily soap:
- Promoter holding dropped drastically in past years.
- New acquirers enter via open offer at ₹62.15.
- CEO resigns in August 2025.
- Chairman changed.
- Independent directors reshuffled.
- Subsidiary sold.
- Land sold for ₹19.56 Cr.
- Another subsidiary stake sold for ₹6.65 lakh.
This isn’t pharma. This is corporate theatre.
Financially, the company reported zero sales in FY23 (yes, zero). Then FY24 sales revived to ₹15 Cr, FY25 to ₹19 Cr, and TTM to ₹25 Cr.
Sales are coming back.
Profits? Not invited yet.
Operating margins remain deeply negative. Inventory days exploded to 359 days in Mar 2025. Debt rose from zero in FY23 to ₹39 Cr in FY25, then reduced to ₹20 Cr by Sep 2025.
The company is either restructuring aggressively… or scrambling.
But here’s the twist:
The open offer price was ₹62.15. That means someone believed there was value.
Now the market disagrees.
Who’s right?
3. Business Model – WTF Do They Even Do?
Pharmaids operates in four broad segments:
1) Specialty Chemicals
Retinol, DL Alpha Tocopherol (Vitamin E), Cyanocobalamin (Vitamin B12), Coenzyme Q10, D-Biotin etc.
Basically: vitamins and active ingredients.
2) Skin Care
Sanitizers, creams, barrier creams — the COVID hangover product line.
3) Hospital Care
Hypochlorite solutions, sprays, PPE.
4) Generics
Branded formulations like Linzomust, Trendyclav-L, Cobasure Gold injection.
So technically, this is a small
